Drug Trial Radar · NCT07848191
Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 Fibrosis
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Oct 7, 2026
Primary completion
Nov 2027
Study completion Nov 2027
Sponsor
- Lead sponsor
- Madrigal Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To determine the safety of Rezdiffra (Resmetirom) when administered alongside common prescriptions for Diabetes Metellus (Farxiga/dapagliflozin \& Actos/pioglitazone)
Conditions
- MASH - Metabolic Dysfunction-Associated Steatohepatitis
Interventions
RezdiffraDrug
All study medications will be administered according to their labels: • REZDIFFRA- Label weight-based dosing: * \<100 kg: 80 mg orally once daily. * ≥100 kg: 100 mg orally once daily
ResmetiromDrug
Resmetirom - weight-based dosing: * \<100 kg: 80 mg orally once daily. * ≥100 kg: 100 mg orally once daily
ACTOS/pioglitazoneDrug
Label dosing recommendations indicated for patients without congestive heart failure (15 or 30 mg orally once daily; if tolerated, increase by 15 mg increments up to a maximum of 45 mg orally once daily for additional glycemic control
FARXIGA/dapagliflozinDrug
Label dosing recommendations indicated for glycemic control in type 2 diabetes (5 mg orally once daily; if tolerated, increase to 10 mg orally once daily for additional glycemic control)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number and Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: From First Dose of newly introduced medication up to 28 weeks
- Number and Percentage of Participants With TEAEs by Maximum SeverityTime frame: From First Dose of newly introduced medication up to 28 weeks
- Number and Percentage of Participants With TEAEs by Relationship to Study MedicationTime frame: From First Dose of newly introduced medication up to 28 weeks
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
Arizona Liver Health - Chandler
Chandler, Arizona · Recruiting
Arkansas Gastroenterology
North Little Rock, Arkansas · Recruiting
Southern California Research Center
Coronado, California · Not yet recruiting
Inland Empire Liver Foundation
Rialto, California · Recruiting
Florida Research Institute
Lakewood Rch, Florida · Recruiting
Gastro Health PLLC Galloway
Miami, Florida · Recruiting
Med Research of Florida, LLC
Miami, Florida · Not yet recruiting
Elevate Clinical Research
Lake Charles, Louisiana · Recruiting
Centricity Research - Morehead City - Multispecialty - PPDS
Morehead City, North Carolina · Recruiting
Gastro Health Research
Cincinnati, Ohio · Recruiting
University Diabetes and Endocrine Consultants
Chattanooga, Tennessee · Not yet recruiting
Texas Clinical Research Institute
Arlington, Texas · Recruiting
South Texas Endocrinology & Metabolism Center
Corpus Christi, Texas · Recruiting
The Liver Institute at Methodist Dallas Medical Center
Dallas, Texas · Recruiting
Elevate Clinical Research - McAllen - PPDS
McAllen, Texas · Not yet recruiting
Diabetes and Glandular Disease Clinic, PA
San Antonio, Texas · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.